Presentation is loading. Please wait.

Presentation is loading. Please wait.

Updates From NOTION: The First All-Comer TAVR Trial

Published byShanna Johnson Modified over 6 years ago

Similar presentations

Presentation on theme: "Updates From NOTION: The First All-Comer TAVR Trial"— Presentation transcript:

1 Updates From NOTION: The First All-Comer TAVR Trial
Lars Sondergaard, MD, DMSc Professor of Cardiology Rigshospitalet Copenhagen, Denmark

2 Disclosure Statement of Financial Interest
Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria BSci, SJM, Symetis BSci, Medtronic, SJM, Symetis

3 Nordic Aortic Valve Intervention Trial The NOTION Trial
Objective: Compare TAVR vs. SAVR in patients >70 years eligible for surgery (all-comers population) Primary outcome: Composite rate of death from any cause, stroke or myocardial infarction at 1 year (VARC II-defined) Secondary outcomes: Safety and efficacy (NYHA), echocardiographic outcomes (VARC II-defined) Design: Prospective, multicenter, non-blinded, randomized trial Enrollment period: December April 2013

4 Enrollment Criteria Main inclusion criteria Main exclusion criteria
Severe AS Age ≥70 years Life expectancy ≥ 1 year Suitable for TAVR & SAVR Main exclusion criteria Severe CAD Severe other valve disease Prior heart surgery Need for acute treatment Recent stroke or MI Severe lung disease Severe renal failure

5 Device and Access Routes
Self-expanding Bioprosthesis (annulus diameter 18-29 mm ) Subclavian Transfemoral 18Fr delivery system 5 5 5

6 Baseline Characteristics
Characteristic, % or mean ± SD TAVR n=145 SAVR n=135 p-value Age (yrs) 79.2 ± 4.9 79.0 ± 4.7 0.71 Male 53.8 52.6 0.84 STS Score 2.9 ± 1.6 3.1 ± 1.7 0.30 STS Score < 4% 83.4 80.0 0.46 Logistic EuroSCORE I 8.4 ± 4.0 8.9 ± 5.5 0.38 NYHA class III or IV 48.6 45.5 0.61

7 Trial Compliance ITT TAVR N=145 ITT SAVR N=135 Baseline 100% (145/145)
(135/135) 1 Month Follow-Up 96.4% (135/140) 92.1% (116/126) 3 Months Follow-Up 96.4% (135/140) 93.6% (117/125) 1 Year Follow-Up 98.5% (134/136) 96.0% (119/124) 2 Year Follow-Up 94.6% (123/130) 95.8% (113/118)

8 Primary Outcome* TAVR 13.1% vs. SAVR 16.3% Composite rate of
death from any cause, stroke or myocardial infarction 1 year after the procedure TAVR 13.1% vs. SAVR 16.3% Absolute difference -3.2%; p=0.43 (for superiority) *Intention-to-treat population

9 All-cause mortality, stroke or MI
Sondergaard et al. Circ carciovasc Interv 2016

10 All-cause mortality, Stroke or MI Patients with STS <4%
Sondergaard et al. Circ carciovasc Interv 2016

11 Functional Class Baseline 3 months 1 year 2 years
Sondergaard et al. Circ carciovasc Interv 2016

12 Valve Performance Δ EOA Δ Mean gradient
Sondergaard et al. Circ carciovasc Interv 2016

13 Aortic Valve Regurgitation
3 months 1 year 2 years Sondergaard et al. Circ carciovasc Interv 2016

14 All-cause mortality in TAVR patients according to PVL rate
Sondergaard et al. Circ carciovasc Interv 2016

15 Conclusions (I) The NOTION trial was the first all-comers trial to randomize lower-risk patients to TAVR or SAVR TAVR was safe and effective, and comparable to SAVR regarding the composite rate of death from any cause, stroke or myocardial infarction after 2 years

16 Conclusions (II) TAVR resulted in larger EOA and lower gradients, but higher rate of moderate PVL than SAVR These two year data support the safety and effectiveness of TAVR in lower risk patients Longer term data on durability and more randomized clinical trials in lower risk patients are necessary

17 All-cause mortality benefits for TAVI
All-cause Mortality at 2 years 4 randomized trials (N =3,806) Trial TAVR SAVR HR (95% CI) PARTNER 1A 116/ /351 0.90 ( ) US CoreValve 85/391 99/359 0.79 ( ) NOTION 11/145 14/135 0.72 ( ) PARTNER 2A 166/ /1021 0.92 ( ) Overall 0.87 ( ), P=0.038 Siontis et al. EHJ 2016, in press

18 RCT in TAVI Extreme High Intermediate Low STS score (%)

19 RCT in TAVI – same age! Extreme High Intermediate Low 100 80 60
STS score (%) Age (years) 40 20

20 Use of surgical bioprosthetic aortic valves Eastern Denmark
68 years 61 years De Backer et al. JACC Cardiovasc Interv 2016

21 NOTION I – Mortality at 2 Years

22 NOTION II Study design Inclusion criteria Primary end-point Design
Severe symptomatic aortic stenosis Age ≤75 years & STS score ≤4% Anticipated usage of aortic bioprosthesis Primary end-point Composite rate of all-cause mortality, stroke & MI at 1 year Design RCT, 1:1, TF TAVI vs. SAVR, superior, N=992 Bicuspid valves & revascularization (CABG or PCI) allowed Any aortic bioprosthesis allowed

Download ppt "Updates From NOTION: The First All-Comer TAVR Trial"

Similar presentations

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.

Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.

Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.

Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk.

Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
University Heart Center Hamburg

University Heart Center Hamburg
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.

The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
UC201300969c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.

UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
G. Michael Deeb, MD On Behalf of the US Pivotal Trial Investigators 3-Year Results From the US Pivotal High Risk Randomized Trial Comparing Self-Expanding.

G. Michael Deeb, MD On Behalf of the US Pivotal Trial Investigators 3-Year Results From the US Pivotal High Risk Randomized Trial Comparing Self-Expanding.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Similar presentations

Ads by Google